Norvir (ritonavir) oral powder, 100 mg packet

On June 7, 2017, the Food and Drug Administration approved a new Norvir (ritonavir) oral powder formulation, 100 mg packet. This approval provides for the use of Norvir (ritonavir) oral powder (only for >100 mg dose increments) in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. Norvir oral powder dosage form is free of alcohol and propylene glycol, both of which are present in the currently marketed Norvir oral solution, making it safer for use in the pediatric population.  Additionally, labeling was revised for the Norvir tablet for oral use and oral solution to reflect the new powder formulation.  The complete revised labeling will be available soon at Drugs@FDA and at DailyMed.  Norvir is manufactured by AbbVie Inc.

Richard Klein Office of Health and Constituent Affairs Food and Drug Administration Kimberly Struble Division of Antiviral Products Food and Drug Administration Steve Morin Office of Health and Constituent Affairs Food and Drug Administration For more information about the HIV Liaison Program visit the FDA Patient Network